AR and cancer: These prostate tumors, which can be classified as AR-negative, androgen-independent (ARneg-AI) cancer, are a subtype of CRPC that have more aggressive characteristics than ARpos-AI prostate cancer and are modeled by established cell lines PC3 and DU145 [8,9].